Effect of electrical stimulation therapy of the lower esophageal sphincter in GERD patients with ineffective esophageal motility

Matthias Paireder1 · Ivan Kristo1 · Reza Asari1 · Gerd Jomrich1 · Johannes Steindl1 · Erwin Rieder1 · Sebastian F. Schoppmann1

Received: 6 June 2020 / Accepted: 16 October 2020 / Published online: 30 October 2020 © The Author(s) 2020

Abstract

Background Electrical stimulation therapy (EST) of the lower esophageal sphincter (LES) is a novel technique in antireflux surgery. Due to the minimal alteration at the LES during surgery, LES-EST is meant to be ideal for patients with gastroesophageal reflux disease (GERD) and ineffective esophageal motility (IEM). The aim of this prospective trial (NCT03476265) is to evaluate health-related quality of life and esophageal acid exposure after LES-EST in patients with GERD and IEM.

Methods This is a prospective non-randomized open-label study. Patients with GERD and IEM undergoing LES-EST were included. Follow-up (FUP) at 12 months after surgery included health-related quality of life (HRQL) assessment with standardized questionnaires (GERD-HRQL) and esophageal functional testing.

Results According to the study protocol, 17 patients fulfilled eligibility criteria. HRQL score for heartburn and regurgitation improved from 21 (interquartile range (IQR) 15–27) to 7.5 (1.25–19), \( p = 0.001 \) and from 17 (11–23.5) to 4 (0–12), \( p = 0.003 \), respectively. There was neither significant improvement of esophageal acid exposure nor reduction of number of reflux events in pH impedance measurement. Distal contractile integral improved from 64 (11.5–301) to 115 (IQR 10–363) mmHg s cm, \( p = 0.249 \). None of the patients showed any sign of dysphagia after LES-EST. One patient needed re-do surgery and re-implantation of the LES-EST due to breaking of the lead after one year.

Conclusion Although patient satisfaction improved significantly after surgery, this study fails to demonstrate normalization or significant improvement of acid exposure in the distal esophagus after LES-EST.

Keywords Electrical stimulation therapy · Gastro esophageal reflux disease · Ineffective esophageal motility · Lower esophageal sphincter

Antireflux surgery is recommended, if lifestyle modification and medical treatment (antacids, proton pump inhibitors (PPI), and histamine 2 (H2–) receptor antagonists) for gastroesophageal reflux disease (GERD) fail [1, 2]. Prior to surgery, manometry and pH metry are crucial tools to assess the presence of GERD and exclude esophageal motility disorders like outflow obstruction, achalasia, or other contractility disorders such as hypercontractile esophagus or absent contractility that may affect outcomes [3, 4]. Interestingly, the evolution of high-resolution manometry re-defined motility disorders like ineffective esophageal motility (IEM) [5]. IEM is known to be associated with advanced GERD highlighted by a high reflux burden during objective testing, whereas its surgical management in context of GERD is still a matter of an ongoing debate [6, 7]. Postoperative dysphagia is a bothersome adverse event that is observed in up to 70% of the patients with severe motility disorders, who undergo laparoscopic fundoplication [8]. Although this may resolve after some period of time or even after interventions, this is still a very troublesome period of time for the patient.

A novel approach of surgical antireflux treatment was the concept of an electrical stimulation therapy (EST) of the lower esophageal sphincter (LES) [9]. It was shown that LES-EST significantly increases the LES pressure without affecting esophageal peristalsis or LES relaxation [10]. Furthermore, the two-year results of a prospective open-label trial were rather promising revealing a significant improvement of symptomatic GERD and esophageal acid exposure.
The idea to improve the competence of the LES without changing anatomical structures is an interesting novel strategy for patients with GERD and IEM. Therefore, this prospective study was designed to evaluate the impact of LES-EST in patients with GERD and IEM. In a preliminary assessment one month after surgery, we could show that there was no impact on postoperative dysphagia and good early symptom control [12].

This is the one-year report of patients with GERD and IEM treated with LES-EST.

Material and methods

Study protocol

This is a prospective, non-randomized, open-label study. The study protocol including inclusion and exclusion criteria was described in detail elsewhere [12]. In brief, patients who fulfilled the criteria of IEM according to the Chicago classification v3.0 were prospectively screened for eligibility [3].

Preoperative workup included upper GI endoscopy as well as esophageal functional testing (EFT) including high-resolution impedance manometry (InSIGHT Ultima®, Sandhill Scientific Inc., USA) and 24 h impedance/pH reflux monitoring (ZepHr®, Sandhill Scientific Inc., USA). Patients were off PPI 15 days prior to testing.

Follow-up took place after 1, 6, and 12 months after surgery and included physical examination, interrogation of the device, and health-related quality of life (HRQL) assessment with standardized questionnaires (GERD-HRQL for heartburn and regurgitation) [13]. Dysphagia was graded from 0 to 4, according to the standardized classification used by Mellow and Pinkas [14]. Esophageal functional testing was repeated during follow-up and presented in this analysis. In patients under PPI treatment, the medication was stopped 15 days prior to EFT.

The ethical committee (EK1217/2017) of the Medical University of Vienna approved the study. All patients gave their written informed consent. This prospective study is registered at clinicaltrials.gov (NCT03476265).

Implantation technique

All patients included in this analysis received laparoscopic implantation of an EndoStim Generation II device (Generation-II-LES-Stimulator Modell 1006). If a hiatal hernia existed, posterior hiatal hernia repair was performed. Two stimulation electrodes were placed under endoscopic control at the anterior side of the gastroesophageal junction approximately 1.5 cm apart and were fixed with 3/0 multifilament, non-absorbable thread, which is applied at least at one side of each silicone butterfly. Correct position of the electrodes and function of the stimulation device was verified using the external programmer. A contrast swallow with Diatrizoate was performed at day one after surgery as well as an abdomen X-ray for documentation of the position of the lead and electrodes. Patients were encouraged to take in soft diet for 4 days [12]. Further medical and technical details of the device and the programming unit were extensively described by Rodriguez 2015 [11].

Statistical analysis

SPSS (Version21.0, SPSS Inc., Chicago, IL, USA) was used for statistical analysis.

All variables were depicted as median and interquartile range (IQR) or 95% confidence intervals (CIs) or mean with standard deviation (SD). GERD health-related quality of life (HRQL) score and esophageal acid exposure before and after treatment were compared with paired Wilcoxon test. P values < 0.05 were considered significant. Graphing was performed with GraphPad Prism (Version 7.0c, GraphPad Software, Inc., La Jolla, CA, USA).

Results

Patient characteristics

Seventeen patients (male = 11, 64.7%) fulfilled the eligibility criteria and underwent implantation of LES-EST with a mean age of 48.9 (SD12.6) years and a mean body mass index of 25 (SD 4.8). Based on BMI, 35.3% of patients were classified as overweight (BMI ≥ 25—< 30) or obese (BMI ≥ 30). Prior to surgery, 11 (64.7%) patients were taking PPI on a regular basis. Twelve patients (70.65%) presented a hiatal hernia. The size of the hernia did not exceed the Hill grade III and were all classified in the preoperative endoscopy as maximum medium sized. All patients had a bothersome history of symptomatic GERD highlighted by a median baseline GERD-HRQL score of 43 (IQR 22–47). Esophageal functional testing revealed a median % time of pH < 4 of 8.9 (IQR 4–21.6) and a median DCI of 64 mmHg s cm, IQR 11.5–301). Further baseline patient characteristics are outlined in Table 1. Details regarding EFT are displayed in Table 2.

Implantation and LES-EST treatment parameters

All procedures were performed minimally invasive by the same surgical team. Median operating time was 45 min (IQR 34–61). In twelve patients (70.65%), a posterior hiatal repair was done. The absence of perforation caused by the electrodes was documented during intraoperative upper gastrointestinal endoscopy. Stimulation parameters were set to 16
sessions for 20 min with 5 mAmp in all patients. Median impedance baseline was 328 (IQR 301.75–366) Ohm. There were no adverse events during surgery.

**Twelve-month follow-up**

All patients fulfilled clinical follow-up and interrogation of the device one year after surgery. HRQL score for heartburn and regurgitation improved to 7.5 (IQR 1.25–19), \( p = 0.001 \) and to 4 (IQR 0–12) \( p = 0.003 \), respectively. Composite HRQL score 12 months after surgery was 12 (3.5–20.8), \( p = 0.003 \); Figs. 1, 2, and 3. Four patients (23.5%) were taking PPIs at least intermittently. 12 months after surgery impedance rose to 514.6 (IQR 412 – 583.5).

Follow-up esophageal functional testing was performed in 14 (82.4%) patients. There was neither significant improvement of acid exposure nor reduction of number of reflux events in pH impedance measurement. DCI improved to 115 (IQR 10–363) mmHg s cm \( p = 0.249 \), registered during manometry. Three (17.6%) patients returned to regular esophageal motility. There were no patients that experienced dysphagia. Further details of the EFT at follow-up are displayed in Table 2 and Figs. 4, 5, and 6. We observed no differences in outcome parameters between patients with or without cruroplasty.

In one patient, 6 months after surgery, the interrogation of the device showed the impedance out of reach. This patient underwent re-laparoscopy and exchange of the stimulation

### Table 1  Patient characteristics

| Characteristic                               | Baseline | 12-month follow-up | \( p^\) |
|----------------------------------------------|----------|--------------------|--------|
| Age, years*                                  | 48.9 (12.6)* |                     |        |
| Body mass index (BMI)*                       | 25.0 (4.8)* |                     |        |
| Gender                                       |          |                    |        |
| Male                                         | 11 (64.7) |                    |        |
| Female                                       | 6 (35.3)  |                    |        |
| BMI class                                    |          |                    |        |
| Normal (<25)                                 | 11 (64.7) |                    |        |
| Overweight (≥ 25 and <30)                    | 4 (23.5)  |                    |        |
| Obese (≥ 30)                                 | 2 (11.8)  |                    |        |
| Patients using daily PPI                     | 11 (64.7) | 4 (23.5)            |        |
| Typical GERD symptoms                        | 11 (64.7) |                    |        |
| Atypical GERD symptoms                       | 9 (52.9)  |                    |        |
| GERD-HRQL score                              |          |                    |        |
| Heartburn (IQR)                              | 21 (15–27)* | 7.5 (1.25–19)* | 0.001  |
| Regurgitation (IQR)                          | 17 (11–23.5)* | 4 (0–12)*            | 0.003  |
| Total (IQR)                                  | 43 (22–47)* | 12 (3.5–20.8)* | 0.003  |

Values in parentheses are percentages unless indicated otherwise

\( PPI \) proton pump inhibitors, \( GERD \) gastroesophageal reflux disease, \( HRQL \) health-related quality of life, \( § \) Paired Wilcoxon test

\( ° \)Values are mean (standard deviation, SD)

\( * \)Values are median (interquartile range, IQR)

### Table 2  Esophageal functional testing – 12-month follow-up

| Characteristic                              | n     | Baseline      | n     | 12-month follow-up | \( P^\) |
|---------------------------------------------|-------|---------------|-------|--------------------|--------|
| Esophageal functional testing                |       |               |       |                    |        |
| Total % pH time < 4                         | 17    | 8.9 (4–21.6)  | 14    | 10.4 (5.6–16.7)    | 0.551  |
| Upright % pH time < 4                       | 17    | 7.8 (1.5–20.3)| 14    | 6.3 (2.8–11.2)     | 0.109  |
| Supine % pH time < 4                        | 17    | 14.4 (1.7–20.7)| 14    | 14.7 (5.0–19.4)    | 0.802  |
| Nr of reflux events                         | 17    | 81 (52.3–100.8)| 10    | 73 (39.3–114.5)    | 0.386  |
| LES resting pressure (mm HG)                | 17    | 15 (12.7–23.4)| 14    | 14.6 (6.3–17.2)    | 0.036  |
| DCI mmHg s cm                               | 17    | 64 (11.5–301) | 14    | 115 (10.0–363.0)   | 0.249  |

Values are median (interquartile range, IQR)

\( LES \) lower esophageal sphincter, \( DCI \) distal contractile integral

\( \circ \)Paired Wilcoxon test
electrodes and pulse generator. The technical assessment of the defective device showed a leakage of the insulation sleeve of the cable. One patient reported esophageal spasms and thoracic sensations at the time of the scheduled LES stimulations. This problem resolved after reduction of the stimulation amplitude to 2.5 mAmp. No further changes were made to the stimulation protocol at the follow-up.

**Discussion**

This is the first one-year report of a prospective open-label study of electrical stimulation therapy of the lower esophageal sphincter in patients with GERD and ineffective esophageal motility. The results show that although patient satisfaction improved significantly, there was no reduction of acid exposure one year after surgery. Moreover, there were no adverse events or side effects such as dysphagia.

Health-related quality of life did significantly improve after surgery and the majority of patients remained
satisfied at 12-month follow-up (composite GERD-HRQL improved from baseline 43 (22–47) to 12 (3.5–22.8). Taking into account, that follow-up pH metry did not show any reduction of acid exposure, this finding is of great interest. Several explanations could be possible. First and foremost, there might be a placebo effect. Although this is less likely one year after surgery, questionnaires are typically of a subjective nature. Initially, the placebo effect was claimed for reducing symptoms of about 35% of the patients [15]. Currently, it is supposed that placebo effect occurs in almost every disease and goes far beyond the 35% published in 1955 [16, 17]. However, there are several studies concerning placebo effect in surgery [18]. Placebo effects are related to the patients’ expectation and the “meaning of surgery” [18]. This has to been differentiated from other non-specific effects such as the natural course of disease or unidentified parallel interventions [19]. Still, a placebo response to LES-EST cannot explain the entire divergence between HRQL and pH metry. But of course, other non-specific effects such as time effect or unknown parallel interventions may influence our findings.

Second, the GERD-HQRL score only represents the symptoms of regurgitation and heartburn. Those are the most frequent symptoms, but still, 52.9% of the patients were also reporting atypical symptoms like persistent cough, hoarseness, or burning in the mouth or throat. However, regarding heartburn and regurgitation, patient reported a significant improvement and the majority were satisfied with symptom control.

Third, electrical stimulation may influence the threshold of symptom perception. It was already stated that a possible explanation could be an interference with the afferent nerve transmission [11]. The combination of patient satisfaction and abnormal acid exposure endorses this theory. However, this possibility still remains to be evaluated.

Importantly, this is the first study, which fails to demonstrate normalization or even a significant improvement of acid exposure in the distal esophagus after LES-EST. In contrast to the two-year results of LES-EST published by Rodriguez et al., this unexpected finding asks for interpretation. The authors describe a significant improvement of acid exposure in the distal esophagus two years after LES-EST [11]. Still, they classify 61% of the patients as “abnormal distal esophageal pH.” As the patient cohort of Rodriguez did not include any patients with IEM, more advanced disease in our population may be responsible for that outcome. Recently, IEM was even associated with dysfunction of chemical clearance [20]. However, comparing our results to patients with defective esophageal motility after fundoplication at least some partial response in acid reduction was expected [21].

Regarding postoperative manometry, we did not see a significant improvement of the distal contractile integral. Nevertheless, we observed the return to regular esophageal motility in 3 patients after LES-EST. Some experimental studies show a possible recovery of esophageal motility after treatment of esophagitis [22, 23]. In a clinical study assessing motility before and after antireflux surgery, IEM resolved after fundoplication in 8.8% of the patients [24]. It is unclear if this is due to a direct effect of stimulation on the esophageal musculature or represents an indirect effect due to sufficient acid control. Follow-up manometry will help to elucidate this return to regular esophageal function more clearly.
Nonetheless, one main goal for antireflux surgery is patient satisfaction and its impact on quality of life. This consists of adequate symptom relief in combination with minimal side effects. While this patient group is at risk for postoperative dysphagia after antireflux surgery, we did not see any signs of negative side effects of LES-EST. This is interesting as it was shown that preoperative DCI is inversely correlated to postfundoplication dysphagia [25].

More than two thirds of our patients underwent additional hiatal hernia repair. As cruroplasty is known to provide significant antireflux effect itself, and subgroup analysis in our small group is not possible, our data are not able to discriminate between the antireflux effect of the LES-EST and the cruroplasty in the patients group that had received both [26].

Our study has some important limitations to address. First of all, the patient number permits only limited interpretation. Sample size calculation was done to detect improvement of GERD-HRQL. Still, an objective confirmation via EFT was to expect. Second, a possible placebo effect, especially in HRQL GERD-HRQL. Nonetheless, one main goal for antireflux surgery is patient satisfaction and its impact on quality of life. This consists of adequate symptom relief in combination with minimal side effects. While this patient group is at risk for postoperative dysphagia after antireflux surgery, we did not see any signs of negative side effects of LES-EST. This is interesting as it was shown that preoperative DCI is inversely correlated to postfundoplication dysphagia [25].

Second, a possible placebo effect, especially in HRQL GERD-HRQL. Still, an objective confirmation via EFT was to expect. Second, a possible placebo effect, especially in HRQL GERD-HRQL. Nonetheless, one main goal for antireflux surgery is patient satisfaction and its impact on quality of life. This consists of adequate symptom relief in combination with minimal side effects. While this patient group is at risk for postoperative dysphagia after antireflux surgery, we did not see any signs of negative side effects of LES-EST. This is interesting as it was shown that preoperative DCI is inversely correlated to postfundoplication dysphagia [25].

Sample size calculation was done to detect improvement of GERD-HRQL. Still, an objective confirmation via EFT was to expect. Second, a possible placebo effect, especially in HRQL GERD-HRQL. Nonetheless, one main goal for antireflux surgery is patient satisfaction and its impact on quality of life. This consists of adequate symptom relief in combination with minimal side effects. While this patient group is at risk for postoperative dysphagia after antireflux surgery, we did not see any signs of negative side effects of LES-EST. This is interesting as it was shown that preoperative DCI is inversely correlated to postfundoplication dysphagia [25].

In summary, this study supports the concept that LES-EST can be especially offered to patients with esophageal dysmotility due to missing gastrointestinal side effects such as dysphagia. However, the study fails to demonstrate a decrease of esophageal acid exposure. Thus, we could not prove the effectiveness of LES-EST through the most objective and robust method, the esophageal pH metry. Furthermore, we failed to achieve improvement in distal LES contraction by LES-EST in this patient group. Patients with GERD and IEM remain a challenging patient group regarding surgical treatment. Further studies are needed to understand the mechanism of LES-EST and its role in GERD treatment.

**Funding** Open access funding provided by Medical University of Vienna. The Upper GI Research group at the Medical University of Vienna received research funding from the company EndoStim.

**Compliance with ethical standards**

**Disclosures** Drs. Matthias Paireder, Ivan Kristo, Reza Asari, Gerd Jomrich, Johannes Steindl, Erwin Rieder, and Sebastian F. Schoppmann have no conflicts of interest or financial ties to disclose. All authors meet the criteria for authorship as set forth in the Consensus Statement on Journal Authorship. Potential conflicts of interest or financial ties are stated further below. Sebastian Schoppmann received an unrestricted research grant from EndoStim.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Pauwels A, Boecxstaens V, Andrews CN, Attwood SE, Bertrinsford R, Bisschops R, Boecxxtaens GE, Bor S, Bredenoord AJ, Cicala M, Corsetti M, Fornari F, Gyawali CP, Hatlebakk J, Johnson SB, Lerut T, Lundell L, Mattioli S, Miwa H, Nafeux P, Omari T, Pandolfino J, Penagini R, Rice TW, Roelandt P, Rommel N, Savarino V, Sifrim D, Suzuki H, Tutuaian R, Vanuytsel T, Vela MF, Watson DI, Zerbib F, Tack J (2019) How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery). Gut 68(11):1928–1941

2. Schwameis K, Oh D, Green KM, Lin B, Zehetner J, Lipham JC, Hagen JA, DeMeester SR (2020) Clinical outcome after laparoscopic Nissen fundoplication in patients with GERD and PPI refractory heartburn. Dis Esophagus. https://doi.org/10.1093/dote/doz099

3. Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, Pandolfino JE, International High Resolution Manometry Working Group (2015) The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 27(2):160–174.

4. Kristo I, Schwameis K, Paireder M, Jomrich G, Kainz A, Schoppmann SF (2018) Dysphagia severity is related to the amplitude of distal contractile integral in patients with Jackhammer esophagus. Neurogastroenterol Motil 30(5):e13276

5. Pandolfino JE, Fox MR, Bredenoord AJ, Kahrilas PJ (2009) High-resolution manometry in clinical practice: utilizing pressure topography to classify esophageal motility abnormalities. Neurogastroenterol Motil 21(8):796–806

6. Gyawali CP, Sifrim D, Carlson DA, Hawn M, Katzka DA, Pandolfino JE, Penagini R, Roman S, Savarino E, Tatsum R, Vaenz M, Clarke JO, Triadalopoulos G (2019) Ineffective esophageal motility: Concepts, future directions, and conclusions from the Stanford 2018 symposium. Neurogastroenterol Motil 31(9):e13584

7. Hiestand M, Abdel Jalil A, Castell DO (2017) Manometric subtypes of ineffective esophageal motility. Clin Transl Gastroenterol 8(3):e78

8. Novitsky YW, Wong J, Kercher KW, Litwin DE, Swanstrom LL, Heniford BT (2007) Severely disordered esophageal peristalsis is not a contraindication to laparoscopic Nissen fundoplication. Surg Endosc 21(6):950–954

9. Rodriguez L, Rodriguez P, Gomez B, Ayala JC, Saba J, Perez-Castilla A, Galvao Neto M, Crowell MD (2013) Electrical stimulation therapy of the lower esophageal sphincter is successful in treating GERD: final results of open-label prospective trial. Surg Endosc 27(4):1083–1092

10. Rodriguez L, Rodriguez P, Neto MG, Ayala JC, Saba J, Berel D, Conklin J, Soffer E (2012) Short-term electrical stimulation of the lower esophageal sphincter increases sphincter pressure in patients with gastroesophageal reflux disease. Neurogastroenterol Motil 24(5):446–450, e213.
11. Rodriguez L, Rodriguez P, Gomez B, Ayala JC, Oxenberg D, Perez-Castilla A, Netto MG, Soffer E, Boscardin WJ, Crowell MD (2015) Two-year results of intermittent electrical stimulation of the lower esophageal sphincter treatment of gastroesophageal reflux disease. Surgery 157(3):556–567
12. Paireder M, Kristo I, Asari R, Jomrich G, Steindl J, Rieder E, Schoppmann SF (2019) Electrical lower esophageal sphincter augmentation in patients with GERD and severe ineffective esophageal motility—a safety and efficacy study. Surg Endosc 33(11):3623–3628
13. Velanovich V (1998) Comparison of generic (SF-36) vs. disease-specific (GERD-HRQL) quality-of-life scales for gastroesophageal reflux disease. J Gastrointest Surg 2(2):141–145
14. Mellow MH, Pinkas H (1984) Endoscopic therapy for esophageal carcinoma with Nd:YAG laser: prospective evaluation of efficacy, complications, and survival. Gastrointest Endosc 30(6):334–339
15. Beecher HK (1955) The powerful placebo. J Am Med Assoc 159(17):1602–1606
16. Walach H, Sadaghiani C, Dehm C, Bierman D (2005) The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials— a secondary analysis. BMC Med Res Methodol 5:26
17. Kienle GS, Kiene H (1997) The powerful placebo effect: fact or fiction? J Clin Epidemiol 50(12):1311–1318
18. Wartolowska K, Judge A, Hopewell S, Collins GS, Dean BJ, Rombach I, Brindley D, Savulescu J, Beard DJ, Carr AJ (2014) Use of placebo controls in the evaluation of surgery: systematic review. BMJ 348:g3253
19. Ernst E, Resch KL (1995) Concept of true and perceived placebo effects. BMJ 311(7004):551–553
20. Dao HV, Matsumura T, Kaneko T, Takahashi S, Tokunaga M, Oura H, Ishikawa K, Akizue N, Kikuchi A, Fujie M, Saito K, Okimoto K, Maruoka D, Nakagawa T, Arai M, Kato J, Kato N (2020) Impact of ineffective esophageal motility on chemical clearance in patients with gastroesophageal reflux symptoms. Dis Esophagus. https://doi.org/10.1093/dote/doaa026
21. Oleynikov D, Eubanks TR, Oelschlager BK, Pellegrini CA (2002) Total fundoplication is the operation of choice for patients with gastroesophageal reflux and defective peristalsis. Surg Endosc 16(6):909–913
22. Zhang X, Geboes K, Depoortere I, Tack J, Janssens J, Sifrim D (2005) Effect of repeated cycles of acute esophagitis and healing on esophageal peristalsis, tone, and length. Am J Physiol Gastrointest Liver Physiol 288(6):G1339-1346
23. Liebermann-Meffert D, Klaus D, Vosmeer S, Allgower M (1984) Effect of intraesophageal bile and acid (HCl) perfusion on the action of the lower esophageal sphincter. Scand J Gastroenterol Suppl 92:237–241
24. Mello MD, Shriver AR, Li Y, Patel A, Gyawali CP (2016) Ineffective esophageal motility phenotypes following fundoplication in gastroesophageal reflux disease. Neurogastroenterol Motil 28(2):292–298
25. Kapadia S, Osler T, Lee A, Borrazzo E (2018) The role of preoperative high resolution manometry in predicting dysphagia after laparoscopic Nissen fundoplication. Surg Endosc 32(5):2365–2372
26. Furnee EJ, Draaisma WA, Gooszen HG, Hazebroek EJ, Smout AJ, Broeders IA (2011) Tailored or routine addition of an antireflux fundoplication in laparoscopic large hiatal hernia repair: a comparative cohort study. World J Surg 35(1):78–84

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.